Lifeworks Advisors LLC Has $10.27 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Lifeworks Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,917 shares of the company's stock after buying an additional 8,125 shares during the quarter. Johnson & Johnson accounts for approximately 1.7% of Lifeworks Advisors LLC's holdings, making the stock its 9th biggest position. Lifeworks Advisors LLC's holdings in Johnson & Johnson were worth $10,268,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Lantz Financial LLC lifted its position in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $453,000. Joel Isaacson & Co. LLC grew its stake in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. State of Wyoming grew its stake in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares during the period. Finally, Range Financial Group LLC grew its position in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after acquiring an additional 2,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Barclays increased their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Bank of America upped their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Down 0.7%

JNJ stock traded down $1.27 during trading hours on Friday, reaching $168.29. 6,199,690 shares of the stock were exchanged, compared to its average volume of 8,375,731. The firm's 50-day moving average is $156.08 and its 200-day moving average is $155.78. The company has a market cap of $404.92 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.16 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.